Behavioral Reaction to Amyloid β Status Disclosure Among Research Participants with High‐AD Risk in Israel Authors: Sapir Golan, Michal S Beeri, Maya Zadok, Mery Ben‐Meir, Yael Rozen, Revital Shutsberg, Ariela Bem‐Moshe, Anthony Heymann, Yossi Azuri, Ithamar Ganmore, Ramit Ravona‐Springer, Chen Hoffmann, Liran Domachevsky, Orit H. Lesman‐Segev Published: 2025 ABSTRACT AbstractBackgroundAmyloid beta (Aβ) deposition marks an early stage in the progression of Alzheimer's disease (AD), detectable in‐vivo years before symptoms emerge and targeted by recently FDA‐approved drugs. This has propelled advancements in understanding, measuring, and treating AD, paving the way for disease prevention in those at risk. However, the psychological impact of disclosing Aβ status to cognitively unimpaired individuals remains underexplored. Our study aimed to evaluate the behavioral responses to Aβ status disclosure in this population.MethodTwo observational studies and two clinical trials incorporating Aβ‐PET were conducted, involving research participants who received information on Aβ‐PET scans, results, and interpretation. Questionnaires were administered before the scan and four‐to‐six months post‐disclosure to assess anxiety, depression, subjective memory complaints, and motivation for risk‐reduction behaviors. Bivariate analysis and mixed models were employed to analyze responses, with logistic regression used to identify predictors of unfavorable responses to negative scan disclosure.ResultAmong 178 participants with amyloid‐negative scans (mean age 64, 57% females) and 21 with amyloid‐positive scans (mean age 77, 38% females), no significant pre‐scan differences were observed. Negative amyloid disclosure correlated with reductions in all domains tested, including memory complaints, depression, anxiety, and motivation to change lifestyle (p≤0.001). Positive amyloid disclosure also resulted in decreases, particularly in anxiety and depression, albeit to a lesser extent and with greater variability (0.007